Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income towards Parent Company: 2018-2024

Historic Income towards Parent Company for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Income towards Parent Company rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Per Silence Therapeutics' latest filing, its Income towards Parent Company stood at -$45.3 million for FY2024, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Silence Therapeutics' 5-year Income towards Parent Company high stood at -$41.8 million for FY2020, and its period low was -$59.3 million during FY2022.
  • For the 3-year period, Silence Therapeutics' Income towards Parent Company averaged around -$52.9 million, with its median value being -$54.2 million (2023).
  • Per our database at Business Quant, Silence Therapeutics' Income towards Parent Company crashed by 67.16% in 2020 and then rose by 16.45% in 2024.
  • Silence Therapeutics' Income towards Parent Company (Yearly) stood at -$41.8 million in 2020, then decreased by 29.74% to -$54.2 million in 2021, then fell by 9.38% to -$59.3 million in 2022, then grew by 8.57% to -$54.2 million in 2023, then increased by 16.45% to -$45.3 million in 2024.